MétaCan
Menu
Back to cohort
Record W4415350852 · doi:10.51731/cjht.2025.1257

Pembrolizumab (Keytruda)

2025· article· W4415350852 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2025
Typearticle
Language
FieldMedicine
TopicCancer Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsChemoradiotherapyCervical cancerPembrolizumabStage (stratigraphy)CancerAdenosquamous carcinomaRadiation therapy

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Keytruda in combination with chemoradiotherapy be reimbursed by public drug plans for the treatment of Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) 2014 stage III to IVA cervical cancer if certain conditions are met. Keytruda in combination with chemoradiotherapy should only be covered to treat patients who have locally advanced cervical cancer (LACC) (stage III to IVA FIGO 2014 classification) that has not been previously treated, with histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix, and who have a relatively good health (as measured by performance status) at the start of treatment. Keytruda in combination with chemoradiotherapy should only be reimbursed if prescribed by clinicians with experience with immuno-oncology and chemoradiotherapy and in treating cervical cancer, and the cost of Keytruda is reduced.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.927
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.319
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicCancer Diagnosis and TreatmentFrench-language works237,207